ginsenoside rh2 has been researched along with Cancer of Prostate in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Alemi, A; Farrokhifar, M; Haghi Karamallah, M; Hamidieh, AA; Hosseini, SA; Soltaninejad, H; Taheri-Kafrani, A; Zare-Zardini, H | 1 |
| Ben-Eltriki, M; Deb, S; Guns, EST | 1 |
| Gao, Q; Zheng, J | 1 |
| Han, Z; Huang, H; Huang, Y; Li, W; Mai, Z; Yuan, R | 1 |
| Hong, B; Niu, T; Wu, S; Zhang, Q | 1 |
| Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C | 1 |
| Jin, F; Kondo, R; Liu, J; Shimizu, K; Yu, H; Zhang, C | 1 |
| Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E | 1 |
| Choi, KJ; Im, DS; Kim, HS; Ko, SR; Lee, EH; Park, JH | 1 |
| Eberding, A; Fazli, L; Gleave, M; Goldenberg, L; Guns, ES; Jia, W; Madera, C; Xie, X | 1 |
| Hill, DL; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhao, Y | 1 |
11 other study(ies) available for ginsenoside rh2 and Cancer of Prostate
| Article | Year |
|---|---|
Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Cholesterol; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Fatty Acids, Monounsaturated; Ginsenosides; Hexoses; Humans; Liposomes; Male; Panax; Particle Size; PC-3 Cells; Prostatic Neoplasms; Quaternary Ammonium Compounds; Tumor Cells, Cultured | 2020 |
1α,25-Dihydroxyvitamin D
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Ginsenosides; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured; Vitamin D | 2021 |
Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Male; MicroRNAs; Prostatic Neoplasms; Protein Biosynthesis; RNA Interference | 2018 |
Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1.
Topics: Animals; Cell Line, Tumor; Endothelial Cells; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms | 2019 |
Inhibition of prostatic cancer growth by ginsenoside Rh2.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Male; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Prostatic Neoplasms; Receptors, Transforming Growth Factor beta; Signal Transduction | 2015 |
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ginsenosides; Humans; Male; Molecular Structure; Panax; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Structure-Activity Relationship | 2010 |
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids | 2010 |
Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Ginsenosides; Growth Inhibitors; Humans; Male; Prostatic Neoplasms | 2004 |
Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Topics: Animals; Antineoplastic Agents; Drug Synergism; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2006 |
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sapogenins; Survival Rate; Triterpenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |